Literature DB >> 2804361

Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants.

N A Kernan1, C Bordignon, G Heller, I Cunningham, H Castro-Malaspina, B Shank, N Flomenberg, J Burns, S Y Yang, P Black.   

Abstract

Risk factors for graft failure were analyzed in 122 recipients of an allogeneic T-cell-depleted human leukocyte antigen (HLA)-identical sibling marrow transplant as treatment for leukemia. In each case pretransplant immunosuppression included 1,375 to 1,500 cGy hyperfractionated total body irradiation and cyclophosphamide (60 mg/kg/d x 2). No patient received immunosuppression prosttransplant for graft-versus-host disease (GVHD) prophylaxis. Nineteen patients in this group experienced graft failure. The major factors associated with graft failure were transplants from male donors and the age of the patient (or donor). Among male recipients of male donor-derived grafts a low dose per kilogram of nucleated cells, progenitor cells (colony forming unit-GM) and T cells was also associated with graft failure. Additional irradiation to 1,500 cGy, high dose corticosteroids posttransplant, and additional peripheral blood donor T cells did not decrease the incidence of graft failure. In addition, type of leukemia, time from diagnosis to transplant, an intact spleen, or the presence of antidonor leukocyte antibodies did not correlate with graft failure. To ensure engraftment of secondary transplants, further immunosuppression was necessary but was poorly tolerated. However, engraftment and survival could be achieved with an immunosuppressive regimen in which antithymocyte globulin and high dose methylprednisolone were administered both before and after infusions of secondary partially T-cell-depleted marrow grafts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804361

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Authors:  Barbara Spitzer; Ann A Jakubowski; Esperanza B Papadopoulos; Kirsten Fuller; Patrick D Hilden; James W Young; Juliet N Barker; Guenther Koehne; Miguel-Angel Perales; Katharine C Hsu; Marcel R van den Brink; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Hugo Castro-Malaspina; Richard J O'Reilly; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-12       Impact factor: 5.742

3.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.

Authors:  Antonia M S Müller; Jessica A Linderman; Mareike Florek; David Miklos; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.

Authors:  Antonia M S Müller; Sumana Shashidhar; Natascha J Küpper; Holbrook E K Kohrt; Mareike Florek; Robert S Negrin; Janice M Brown; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-22       Impact factor: 11.205

5.  Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Authors:  Jenna D Goldberg; Junting Zheng; Ravin Ratan; Trudy N Small; Kuan-Chi Lai; Farid Boulad; Hugo Castro-Malaspina; Sergio A Giralt; Ann A Jakubowski; Nancy A Kernan; Richard J O'Reilly; Esperanza B Papadopoulos; James W Young; Marcel R M van den Brink; Glenn Heller; Miguel-Angel Perales
Journal:  Leuk Lymphoma       Date:  2017-01-10

6.  T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

Authors:  Ann A Jakubowski; Trudy N Small; Nancy A Kernan; Hugo Castro-Malaspina; Nancy Collins; Guenther Koehne; Katharine C Hsu; Miguel A Perales; Genovefa Papanicolaou; Marcel R M van den Brink; Richard J O'Reilly; James W Young; Esperanza B Papadopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

7.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

8.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

9.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

10.  Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Authors:  Michael Scordo; Valkal Bhatt; Patrick Hilden; Melody Smith; Katie Thoren; Christina Cho; Gunjan L Shah; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Scott T Avecilla; Richard J O'Reilly; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Jaap J Boelens; Miguel-Angel Perales; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.